



SENTIO Protect

'Our opinion, your success'

TESTING PLATFORM UPDATE –OMICRON VARIANT OF CONCERN

The manufacture of the cue molecular test we use for our onboard test platform has confirmed to us that their team of scientists and bioinformatic experts have successfully validated the test for detecting the new Omicron variant. This is based on an analysis of the SARS-CoV-2 B.1.1.529 variant, designated by the World Health Organization as Omicron, using information from the GISAID database. Specifically, they found that 99.2% of the 127 published sequences are a perfect match to the primers in used in the test, which uses molecular (NAAT) technology.

How was this validated so quickly?

The manufacture is actively monitoring the mutations of COVID-19, so they can ensure the test can detect them. They implemented a surveillance program in the early stages of the pandemic to monitor and analyse all relevant SARS-CoV-2 variant sequences globally. This involves routinely checking their COVID-19 test primers, the targeting mechanism the molecular test uses, against these sequences to ensure these mutations do not affect the sensitivity or specificity of the test.

Their scientists found that the accuracy of the test has remained unaffected by the mutations in the Omicron variant and other variants of concern to date.

In coordination with the manufacturer, we will continue to evaluate their molecular COVID-19 NAAT test against new and emerging variants and will update you with any further developments.

Clinical Lead
S.Hepburn
Clinical Scientist, HCPC Registered

CEO
James Hammond

SENTIO Protect Ltd, 3 Lloyd's Avenue, London, EC3N 3DS, UK
Registered in England No. 13003090. Registered office: Kemp House, 160 City Road, London, EC1V 2NX, UK.
T. +44 207 111 0817 E. info@sentioprotect.com

Part of the **SENTIO** Group

SENTIO Group Ltd, 3 Lloyd's Avenue, London, EC3N 3DS, UK
Registered in England No. 12998501. Registered office: Kemp House, 160 City Road, London, EC1V 2NX, UK.



sentioprotect.com